Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Pick a track — progress rings update as you complete lessons.
8 lessons
9mRetatrutide keeps stacking strong data, and the latest trial update sharpens the path toward an FDA submission. The bigger story is not just weight loss. It is how the triple-agonist profile may change what obesity medicine expects from a next-wave therapy.
10mOrthopaedics is paying closer attention to peptides because the field keeps running into the same problem: recovery is biology, but biology still needs evidence before it becomes a protocol.
9mRetatrutide's weight-loss signal is now strong enough that people are comparing it with surgery. That comparison is useful, but only if you understand what the numbers do and do not mean.
7mA 2025 Biomolecules review highlights the hardest GLP-1 question: what happens after the weight comes off? Maintenance needs a plan before the final dose.
7mEDS changes the safety conversation around peptides. GHK-Cu, BPC-157, and TB-500 are discussed for tissue support, but EDS plus cardiac history should stay clinician-led.
5mLearn the proper technique for reconstituting NAD+ vials, understanding concentration calculations, and building an effective dosing protocol for your research needs.
9mMOTS-C activates AMPK through mitochondrial signaling. NAD+ feeds the cellular energy substrate. Together, they hit the same system from two different angles — and the results are additive.
11mDiscover the key differences between CJC-1295 with DAC and CJC-1295 without DAC, and which is better for your needs.
Also available at /blog for legacy links.